GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biodexa Pharmaceuticals Plc (LSE:BDRX) » Definitions » Debt-to-Revenue

Biodexa Pharmaceuticals (LSE:BDRX) Debt-to-Revenue : 2.80 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Biodexa Pharmaceuticals Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Biodexa Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.17 Mil. Biodexa Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.30 Mil. Biodexa Pharmaceuticals's annualized Revenue for the quarter that ended in Dec. 2023 was £0.17 Mil. Biodexa Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 2.80.


Biodexa Pharmaceuticals Debt-to-Revenue Historical Data

The historical data trend for Biodexa Pharmaceuticals's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biodexa Pharmaceuticals Debt-to-Revenue Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.02 0.76 1.33 0.89 1.22

Biodexa Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.16 0.76 1.35 0.91 2.80

Competitive Comparison of Biodexa Pharmaceuticals's Debt-to-Revenue

For the Biotechnology subindustry, Biodexa Pharmaceuticals's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biodexa Pharmaceuticals's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biodexa Pharmaceuticals's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biodexa Pharmaceuticals's Debt-to-Revenue falls into.



Biodexa Pharmaceuticals Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Biodexa Pharmaceuticals's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.169 + 0.295) / 0.381
=1.22

Biodexa Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.169 + 0.295) / 0.166
=2.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


Biodexa Pharmaceuticals Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biodexa Pharmaceuticals's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biodexa Pharmaceuticals (LSE:BDRX) Business Description

Traded in Other Exchanges
Address
1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals Plc is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.